Biohaven Faces FDA Enrollment Hold & AbbVie Reports Menstrual Migraine Results

Biohaven found a problem in its own rodent data, called the FDA about it, and got a partial clinical hold — sixteen days after licensing that same drug to SK Biopharmaceuticals for up to seven hundred ninety-five million dollars.

Plus a top-twenty Novartis shareholder wants the board rebuilt after two Phase 3 failures, NICE just told Gilead no on the NHS, and AbbVie has a Phase 3 win in a migraine segment nobody owns. It's a heavy Thursday. Let's get into it.

Welcome to The Pharma Closeout for Thursday, September tenth. I'm Alex Mercer.

And I'm Maya Patel.

So, Biohaven — the partial hold on opakalim, BHV-7000, their Kv7 potassium channel activator in refractory focal epilepsy. New enrollment stops. Dosing continues. And here's the figure that reframes the whole thing: sixteen days before that hold letter, Biohaven licensed the Kv7 platform to SK Biopharmaceuticals for up to seven hundred ninety-five million dollars.

Start with how it happened, though, because the sequence is the story. No patient event triggered this. Biohaven found a metabolite in routine nonclinical rodent characterization and took it to the agency itself. A hold you asked for reads very differently from a hold you got handed.

Right — and the trial that matters was already locked. BHV7000-303, the pivotal, was fully enrolled and randomized before the letter. The second-half topline is untouched.

The readout is untouched. The path after it isn't.

Push on that.

Say the topline reads positive in November and the metabolite work still isn't closed. Biohaven then owns a winning pivotal trial with no clean route to a filing. The company says the rodent finding may be species-specific and expects clarifying data within weeks. Weeks is a plan. And the eight-K is explicit that when enrollment resumes is uncertain — so the one date they can't give you is the one that governs everything else.

Here's where I think the market misread it, though. Biohaven handed SK all the clinical and nonclinical data — the metabolite findings included — before the August twenty-sixth signing. SK didn't get surprised. SK priced this.

SK priced the finding. It didn't price the agency's reaction to the finding. Those are two different risks, Alex, and only one of them showed up in a letter.

I'll take the narrower version — they knew the data, not the response. But the reason SK moved anyway is a clock, and that clock hasn't stopped. Xenon's azetukalner is another Kv7 opener in Phase 3 for focal onset seizures. Positive topline from X-TOLE2 already reported, NDA submission signaled for this quarter.

Then the cost of this hold isn't scientific, it's positional. Biohaven's pivotal data still lands on schedule. SK brings real US epilepsy infrastructure — they built it around Xcopri. But you pause enrollment for an unspecified stretch while your closest mechanistic competitor is filing, and second-to-market quietly becomes third.

And that lands on SK's side of the table. They're still working toward closing, and three hundred fifty million becomes payable when they get there. So the gating item on a seven hundred ninety-five million dollar deal is no longer the epilepsy data — it's a rodent metabolite study that hasn't reported.

Which is what I'd watch, and specifically the species-specificity question. If the metabolite doesn't translate to humans, this is a footnote by year-end and everyone moves on. If it does translate, nobody's going to care what the pivotal trial showed.

Shifting to the deal side — and this one runs the other direction on risk appetite. Frazier Life Sciences closed more than one point one billion dollars in fresh commitments to its public biotech fund, oversubscribed, taking that vehicle to roughly two point eight billion since 2021. They're pointing at the exits to make the case: Verona Pharma to Merck for ten billion, Alpine Immune to Vertex for four point nine.

A long-only mandate in small and mid-cap biotech is the least defensive thing an institution can do right now. That's money getting positioned ahead of the next approval-and-acquisition wave, not chasing one that already happened.

Also worth noting — Takeda said Andy Plump retires as R&D president in June of next year. He came in twenty fifteen, built the rare disease business out of Shire, and he's timing the exit well: approvals landed last month for the narcolepsy drug Orzeyful and the blood cancer therapy Mimrylo, with zasocitinib behind them on positive Phase 3 psoriasis data.

He's also handing over the Entyvio patent cliff and a cell therapy exit that's still recent history. His successor inherits a pipeline that finally delivered against a revenue base about to be tested — which makes the succession pick the strategic decision at Takeda, not a personnel note.

On the regulatory side — NICE issued draft guidance recommending against NHS coverage of Gilead Sciences' lenacapavir for HIV pre-exposure prophylaxis. Cost-effectiveness estimates landed above the range NICE considers an acceptable use of NHS resources, with flagged uncertainties in both the clinical evidence and the economic model.

So the science didn't lose this.

The science didn't lose this. NICE accepts that the trial data show lenacapavir cuts HIV risk better than oral PrEP. Its argument is about what England already has — oral generics for most people, and GSK's Apretude every two months for those who can't take a pill. Lenacapavir has never been compared head-to-head with cabotegravir; indirect comparison suggests it likely works as well. Superiority over the comparator the payer isn't using doesn't buy you access.

And that's a UK access barrier on an asset outperforming its model everywhere else. Yeztugo cleared two hundred thirty-two million in second-quarter sales — about eight percent ahead of what analysts had it at.

NICE reconvenes November third to re-weigh the evidence and the comments filed against this draft. UK charities have already said out loud that this comes down to price. Which means the committee isn't the one who moves next — Gilead is.

Quick note before our second story — if The Pharma Closeout is how you close out your pharma day, follow the show on Spotify or Apple Podcasts. Now — David Samra of Artisan Partners, a top-twenty Novartis holder, told Reuters today that Chairman Giovanni Caforio needs to make changes at board level and tighten oversight on dealmaking. On the acquisition team, his words: uninspiring at best.

Two Phase 3 failures in the same week is what put him on the record. Del-desiran missed in myotonic dystrophy type 1 — the centerpiece asset of the twelve billion dollar Avidity acquisition — days after pelacarsen missed in secondary cardiovascular prevention. Both externally sourced. That's the pattern he's pointing at, not the individual misses.

And the market didn't wait for the pattern. Shares fell more than ten percent, erasing nearly thirty billion in market cap. Samra then reached back to MorphoSys, two point nine billion in twenty twenty-four — pelabresib has carried a safety signal since, an imbalance in malignant transformations that pushed the FDA filing plan.

Note what he isn't attacking, though. He said Narasimhan has done a very good job. The complaint is diligence, not strategy. And Novartis has real counter-evidence: guidance unchanged pre- and post-2030, and Vanrafia out of the three point five billion dollar Chinook deal got approved.

So the thread is whether one holder becomes a bloc. A top-twenty investor naming the chairman in print either dies quietly over the next month, or it turns up on a proxy.

Now, looking ahead — AbbVie's Phase 3 Luna trial hit its primary endpoint in menstrual migraine. Qulipta cut migraine days by an average of one point two versus zero point four on placebo, and all eight ranked secondary endpoints came in. They're filing with global regulators for the label expansion.

The dosing is the part I'd flag. Seven consecutive days starting three days before menses, measured across three cycles — that's intermittent use inside a chronic preventive franchise. And AbbVie's own framing is that nothing is specifically approved here today.

Which tells you what the filing is for. Qulipta did roughly one point zero four billion last year, and with Ubrelvy the migraine franchise cleared two point three billion. This isn't a share grab against Nurtec or Emgality — it's claiming a segment none of them have a label in.

Also landing today — CSL Seqirus published Phase 3 results in The Lancet Infectious Diseases for its adjuvanted cell-based higher-dose flu vaccine, AUJEMFLU. Adults fifty and older, across eight countries. Superiority over the adjuvanted egg-based comparator on all four strains, and non-inferiority to the recombinant vaccine on three of four strains in the fifty-plus group, four of four in the sixty-five-plus.

And publishing it now, ahead of the northern hemisphere season, isn't incidental. That's the evidence package built for national immunization advisory groups deciding enhanced vaccination strategy for older adults — the committees, not the prescribers, are the audience.

Heavy day. A clinical hold sitting on top of a live licensing deal at Biohaven, an activist naming the chairman at Novartis, NICE saying no to lenacapavir, and AbbVie's Luna win.

The one I'll be sitting with is that rodent metabolite. Weeks, they said — and that answer decides whether a clean pivotal readout is worth anything at all. Have a good evening, everyone.

Follow the show on Apple Podcasts, Spotify, or wherever you listen — a quick rating or share helps other listeners find us. Tomorrow's briefing lands on its own.